<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human Vgamma2Vdelta2 T cells recognize nonpeptide antigens derived from pathogenic microbes in a TCR-dependent manner, such as pyrophosphomonoester compounds from mycobacteria and <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> parasite and alkyl <z:chebi fb="39" ids="32952">amines</z:chebi> from Proteus, suggesting that this subset of gamma delta T cells is involved in infectious immunity </plain></SENT>
<SENT sid="1" pm="."><plain>The precise recognition mechanism has been delineated using a site-directed mutagenesis strategy based on crystal structure of gamma delta TCR </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand, several lines of evidence indicate that human gamma delta T cells are involved in <z:e sem="disease" ids="C1519680" disease_type="Disease or Syndrome" abbrv="">tumor immunity</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Although activated gamma delta T cells exhibit a cytolytic activity against most of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, only a small fraction of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, like Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and multiple myeloid cells, is recognized by human gamma delta T cells in a TCR-dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain>This implicates that human gamma delta T cells have two distinct pathways for anti-<z:e sem="disease" ids="C1519680" disease_type="Disease or Syndrome" abbrv="">tumor immunity</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>One is a natural killer-like pathway and the other is a TCR-dependent pathway </plain></SENT>
<SENT sid="6" pm="."><plain>Recently, it was shown that treatment of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells with nitrogen-containing bisphosphonates, therapeutic drugs for <z:hpo ids='HP_0003072'>hypercalcemia</z:hpo> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, generated antigenic structure on the surface of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, which could be recognized by human gamma delta T cells in a TCR-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain>This <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> labeling system may lead to a novel strategy for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy </plain></SENT>
</text></document>